anti runx2  (Cell Signaling Technology Inc)

Journal: Bioactive Materials

Article Title: MSC-mimicking nanovesicle embedded bio-adhesive hydrogel for dual immunomodulation and osteogenesis to promote maxillofacial bone regeneration

doi: 10.1016/j.bioactmat.2026.02.032

Figure Lengend Snippet: In vivo evaluation of bone regeneration after hydrogel implantation in the mandibular bone defect mouse model. a) Schematic illustration of the mandibular bone defect mouse model. b) Micro-CT 3D reconstruction images of the mandibular bone samples at 4 and 8 weeks post-surgery. Scale bar = 1 mm. c) Semi-quantitative analysis of BV/TV, bone surface, Tb.N and Tb.sp (n = 6) in mouse mandibular bone defects implanted with different hydrogels at 8 weeks post-surgery. d) H&E staining and Masson trichrome staining of tissue sections of mandibular defects at 8 weeks post-surgery. Scale bar = 100 μm. e, f) Immunofluorescent staining images and corresponding semi-quantitative analysis of the expression levels of RUNX2 and OCN in mandibular bone defect areas at 4 and 8 weeks post-surgery (n = 3). Scale bar = 50 μm. P-values are calculated using one-way ANOVA with Tukey's test, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, n.s. not significant ( a was created with bioRender. com).

Article Snippet: After blocking with 5% skimmed milk (diluted with TBST), the membranes were probed with the primary antibodies for CD90 (1:1000, Cat. ab92574, Abcam, UK), CD146 (1:1000, Cat. ab75769, Abcam, London, UK), CD105 (1:500, Cat. sc18838, Santa, USA), CXCR4 (1:250, Cat. 35-8800, Invitrogen, CA, USA), Na + /K + ATPase (1:1000, Cat. sc28800, Santa, USA), BMP2 (1:1000, Cat. ab284387, Abcam, UK), RUNX2 (1:1000, Cat. 12556, Cell Signaling Technology, USA) and β -actin (1:10000, Cat. T0022, Affinity, China) overnight at 4 °C, followed by bathing with horseradish peroxidase (HRP) conjugated secondary antibodies (1:5000, Cat. S0002 or Cat. S0001, Affinity, China).

Techniques: In Vivo, Micro-CT, Staining, Expressing

Journal: Bioactive Materials

Article Title: MSC-mimicking nanovesicle embedded bio-adhesive hydrogel for dual immunomodulation and osteogenesis to promote maxillofacial bone regeneration

doi: 10.1016/j.bioactmat.2026.02.032

Figure Lengend Snippet: The PEG-pp@nMSC@MT hydrogel effectively promotes BMMSCs' osteogenesis in vitro . a) Schematic illustration of co-culture BMMSCs with hydrogels. b) ALP staining of BMMSCs co-cultured with different scaffolds after 7 days. Scale bar = 500 μm. c) Semi-quantitative analysis of ALP staining (n = 3). d) ARS staining of BMMSC co-cultured with different scaffolds after 21 days. Scale bar = 500 μm. e) Semi-quantitative analysis of ARS staining (n = 3). f) mRNA expression of osteogenic genes (BMP2, OCN, and RUNX2) of BMMSCs treated with different hydrogels in the MMP condition after 5 and 10 days (n = 3). g) Western blot analysis of osteogenic protein (BMP2 and RUNX2) of BMMSCs treated with different hydrogels in the MMP condition after 7 and 14 days. P-values are calculated using one-way ANOVA with Tukey's test, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, n.s. not significant ( a was created with bioRender. com).

Article Snippet: After blocking with 5% skimmed milk (diluted with TBST), the membranes were probed with the primary antibodies for CD90 (1:1000, Cat. ab92574, Abcam, UK), CD146 (1:1000, Cat. ab75769, Abcam, London, UK), CD105 (1:500, Cat. sc18838, Santa, USA), CXCR4 (1:250, Cat. 35-8800, Invitrogen, CA, USA), Na + /K + ATPase (1:1000, Cat. sc28800, Santa, USA), BMP2 (1:1000, Cat. ab284387, Abcam, UK), RUNX2 (1:1000, Cat. 12556, Cell Signaling Technology, USA) and β -actin (1:10000, Cat. T0022, Affinity, China) overnight at 4 °C, followed by bathing with horseradish peroxidase (HRP) conjugated secondary antibodies (1:5000, Cat. S0002 or Cat. S0001, Affinity, China).

Techniques: In Vitro, Co-Culture Assay, Staining, Cell Culture, Expressing, Western Blot

Journal: Journal of Nanobiotechnology

Article Title: Nanoparticle-integrated smart hydrogel with H 2 S-triggered antibacterial escalation and sustained oxygen release for periodontal regeneration

doi: 10.1186/s12951-026-04535-7

Figure Lengend Snippet: Osteogenic differentiation of hPDLSCs induced by PDA@Hb/NOCG. ( A ) Representative ALP staining results of hPDLSCs after 7 days of osteogenic differentiation. ( B ) Alizarin Red S staining of hPDLSCs after 21 days of osteogenic induction. ( C ) Quantitative analysis of ALP staining in hPDLSCs. ( D ) Quantification of Alizarin Red S staining in hPDLSCs. ( E-K ) Relative mRNA expression levels of osteogenesis-related genes in hPDLSCs, including ALP, BMP2, COL1A1, OPG, RUNX2, OPN, and OCN, normalized to GAPDH. ( L-O ) Protein expression levels of osteogenesis-related markers in hPDLSCs, including ALP, RUNX2, and β-catenin, and their corresponding quantitative analysis. ( P ) Protein expression levels of osteogenesis-related markers, including ALP, RUNX2, and β-catenin, in hPDLSCs under different treatment conditions with or without DKK1. ( Q ) Corresponding quantitative analysis of ALP, RUNX2, and β-catenin protein expression in each group

Article Snippet: Primary antibodies against ALP (rabbit polyclonal IgG, Cat. No. 18507-1-AP), NF-κB p65 (rabbit polyclonal IgG, Cat. No. 10745-1-AP), and β-catenin (rabbit polyclonal IgG, Cat. No. 17565-1-AP) were purchased from Proteintech (Wuhan, China), while the antibodies against RUNX2 (rabbit polyclonal IgG, Cat. No. HY- P80316 ) and Hb (polyclonal antibody, Cat. No. PAB409Bo01) were obtained from MedChemExpress (MCE, Shanghai, China) and Cloud-Clone Corp. (Wuhan, China), respectively.

Techniques: Staining, Expressing